The network of networks: LinkHealth@BW connects the life sciences ecosystem
What if the committed players in the life sciences ecosystem in Baden-Württemberg joined forces to share resources such as information, support or contacts via a central platform? What if it was a one-stop shop for questions like: Where is the best place for my life sciences start-up or life sciences investment? We at Pfizer Healthcare Hubs are proud that we were able to help shape the development of such a platform with LinkHealth@BW!
LinkHealth@BW offers an ecosystem with a focus on health in Baden-Württemberg, which supports companies, start-ups, research and development institutions, municipalities, networks and talents in their search for information, support, financing, networking and cooperation both nationally and internationally, thus strengthening innovations and new technologies in the health sector in a targeted manner.
Achieving more together
Together with over 20 organizations, networks and companies, we have joined forces to form the "LinkHealth@BW" initiative to offer all participants the most diverse and far-reaching offer for questions and concerns about the healthcare industry. Thanks to the excellent linking of the committed partners, all participants and their networks have access to a true pool of expert knowledge, contacts and industry insights.
"As a network of networks, LinkHealth@BW offers all interested parties unique access to the life sciences ecosystem in Baden-Württemberg – which is excellently positioned with its strong partners and is unparalleled nationally and internationally," says Dr. Barbara Jonischkeit, Head of Health and Bioeconomy at BIOPRO.
Get in touch!
The initiative LinkHealth@BW was developed within the framework of the Forum Gesundheitsstandort Baden-Württemberg and can be found under the project title: "Further development and integration of the innovation ecosystems of the state in the field of life sciences as a basis for national and international appeal".
For all questions about start-ups, projects or scaling in the field of life sciences, to which you have not found any answers elsewhere, they are certainly available in the LinkHealth@BW cosmos – feel free to contact us, we will establish a corresponding contact!
Schreibt uns!
Looking ahead with courage and optimism: A look back at the "IHK-Heimspiel"
Football and entrepreneurship - this was the motto of the IHK home game, the annual conference of the IHK Südlicher Oberrhein, for which 900 representatives of the regional economy, politics, administration and social institutions met yesterday in the Europapark stadium. But it was also about the question: How do we want to shape economic development in these difficult times? Eberhard Liebherr, President of the IHK Südlicher Oberrhein called for staying optimistic right now and moving forward.
How can such a “going forward” look like?
There were a variety of approaches that evening, two of which were discussed on stage:
The first answer came from Holger Stanislawski, a former player and coach at FC St. Pauli and now a supermarket owner. He reported on the legendary FC St. Pauli derby at Hamburger SV in 2011. As FC coach, he switched on the third goalkeeper and initially caused amazement. The plan worked: St. Pauli won against HSV for the first time since 1977.
His conclusion: If you want to be successful, you have to think outside the box, be courageous, and try out new paths. And don't be afraid of failure.
The second half of the IHK home game belonged to the startups
Three startups from the region presented what courageous progress can look like in concrete terms: Bauta, dotscene and Titan. All three can look back on an impressive development that shows: It pays to courageously advance innovations.
For startups there are the best network partners in the region, from social innovation to crafts and life sciences - these had their say after the startups: Malaika Lauk from Baden.Campus, Mona Feist from Black Forest Innovation, Leonard Sporleder from Grünhof and Nikolai Sexauer from Startinsland and Yannick Haldenwanger from StartUp.connect. Peter Neske, Innovation Lead of the Pfizer Healthcare Hub, also reported on how Pfizer advances startups through cooperation.
An inspiring event that also provided a great stage for start-up initiatives, accelerators and startups!
Pfizer Challenge on Adherence in Clinical Studies
"Drugs don't work in patients who don't take them," said C. Everett Coop, former US Surgeon General. A particular problem is non-adherence in clinical studies. The Pfizer Breakthrough Change Accelerator has therefore launched an adherence challenge: New, innovative, patient-friendly solutions are being sought for the continuous improvement of investigational product adherence in clinical studies.
Non-adherence in clinical studies jeopardizes the integrity of the study. Non-adherent study participants can lead to the following results:
- Increased the number of patients required to complete a study
- Increased costs (higher site and patient recruitment)
- Increased time to complete the study
- Increased investigational products overage and associated costs
The Pfizer Breakthrough Accelerator is therefore looking for new, innovative, patient-friendly solutions to continuously improve the adherence of investigational medicinal products in clinical trials. The solution should also allow for the prediction, assessment, and identification of potential risk factors contributing to clinical trial non-adherence in clinical trial participants.
Goals of the challenge
- Solutions that provide support and motivation to remain adherent with investigational products as well as visit schedules throughout their trial
- Provide insights and analytics to better predict the adherence curve for clinical trial participants to allow for appropriate intervention to maintain investigational product adherence.
- Capture adherence metrics back to the study teams
What's in it?
1. Opportunity to participate in a Phase 2 Study
Winners, upon Pfizer’s request, will first negotiate in good faith with Pfizer for the right of Pfizer to develop and/or license Entrant’s solution, including further changes and/or developments made thereof during the Challenge. Funds of up to $200,000 will be paid based on milestones and scope of work. To avoid any doubt, winning the Challenge does not automatically lead to further legally binding contractual agreements with Pfizer. The detailed terms of possible future agreements between Pfizer and the winner (or any of the Entrants) will be negotiated separately and will not be linked to the Term set herein.
2. Mentoring and Guidance
Pfizer experts from various areas are available to the winning team for up to 20 hours of mentoring. Together with the winner, Pfizer will work out the exact needs and goals of the mentoring in order to provide information and to connect the winner with the suitable mentors.
In case you have any questions regarding the Challenge please contact the organizing team at Pfizer under [email protected]
More inforation about the challenge
i4Challenge 2022 is now open for applications!
Have you developed innovative solutions, new approaches, next-generation products or services for the digital transformation of Industry 4.0? Then the i4Challenge is the right place for you! SMEs, startups and individuals can apply for the challenge until the end of July.
Focused on innovative solutions, new approaches and next generation products or services for industrial transformation, the i4Challenge offers a platform to help SME’s, startups and Industry 4.0 projects promote their products or services. The ultimate goal of the program is to enable a thriving production technology and industrial innovation ecosystem.
Depending on the stage of the project, applicants can register for one of the two categories "New Idea" or "Innovative Solution".
Learn more and apply today